PRODUCTION OF CLINICAL GRADE DNA VECTORS EXPRESSING CO-STIMULATORY MOLECULES FOR ENHANCING THE EFFECT OF SPECIFIC ANTIGEN-PEPTIDE VACCINATION IN CANCER PATIENTS.
Commerce Business Daily
PRODUCTION OF CLINICAL GRADE DNA VECTORS EXPRESSING CO-STIMULATORY MOLECULES
FOR ENHANCING THE EFFECT OF SPECIFIC ANTIGEN-PEPTIDE VACCINATION IN CANCER
PATIENTS.
National Cancer Institute Technology Transfer Branch CRADA Opportunity
Announcement Summary: The National Cancer Institute (NCI) is currently
seeking a Collaborator for a Cooperative Research and Development
Agreement (CRADA) to work with investigators in the Center for Cancer
Research (CCR) to develop DNA vectors expressing co-stimulatory molecules
for enhancing the effect of peptide vaccines. Proposed NCI Contribution:
The NCI investigators have developed a new strategy to enhance the
vaccination of patients with peptides. The NCI investigators would like
to utilize this technology to treat patients with cancer. Accordingly,
the NCI investigators will develop and conduct clinical trials to utilize
these reagents in the treatment of cancer patients. Proposed CRADA
Collaborator Contribution: The Collaborator will develop clinical grade
DNA vectors expressing the specific co-stimulatory molecules. Proposed
Joint Contribution: NCI and the Collaborator will jointly design a CRADA
research plan and will jointly interpret the data generated under the
research plan. Selection Criteria for Choosing the CRADA Collaborator May
Include: 1. A demonstrated background and expertise in production of
clinical grade DNA vectors. 2. A demonstrated record of success in the
commercial development and production of products related to this area of
technology. 3. The willingness to commit best effort and demonstrated
resources to the research and development of the DNA vectors for clinical
use. 5. The level of financial and staffing support the CRADA
Collaborator will provide for CRADA-related activities. 6. The
willingness to cooperate with the NCI in the timely publication of
research results. 7. The agreement to be bound by the appropriate
Department of Health and Human Services (DHHS) regulations relating to
human subject research and to all Public Health Service (PHS) policies
relating to the use and care of laboratory animals. 8. The willingness to
accept the legal provisions and language of the CRADA. These provisions
govern the distribution of future patent rights to CRADA inventions.
Generally, the rights of ownership are retained by the organization that
is the employer of the inventor with (1) the grant of a license for
research and other Government purposes to the Government when the CRADA
Collaborator's employee is the sole inventor, or (2) the grant of an
option to elect an exclusive or nonexclusive license to the CRADA
Collaborator when the Government employee is the sole inventor. Response
Procedure: Interested parties should notify the Technology Transfer
Branch of the NCI in writing of their interest in the CRADA collaboration
no later than November 28, 2001. The written notice should briefly
address the selection criteria listed above. Contact Information: CRADA
Contact: Suzanne M. Frisbie, Ph.D. 6120 Executive Boulevard, Suite 450
Rockville, Maryland 20852 Phone: 301-496-0477; Fax: 301-402-2117 E-mail:
Fris...@otd.nci.nih.gov WEB: Click here to view the standard NIH CRADA
document., http://ttb.nci.nih.gov/forms.html. E-MAIL: Click here to send
a message to the CRADA point of, Fris...@otd.nci.nih.gov. Posted
11/02/01 (W-SN5121P0).